"The voice of oncology in Massachusetts."

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

August 16, 2023 8:18 AM | Katy Monaco (Administrator)

Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.  Read More.

View full prescribing information for Elrexfio including box warning and medication guide.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software